Chura Justin C, Van Iseghem Kelin, Downs Levi S, Carson Linda F, Judson Patricia L
Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA.
Gynecol Oncol. 2007 Nov;107(2):326-30. doi: 10.1016/j.ygyno.2007.07.017. Epub 2007 Aug 15.
To investigate the efficacy and safety of bevacizumab in heavily pretreated patients with recurrent ovarian cancer.
Patients with recurrent ovarian cancer were treated with intravenous bevacizumab 10 mg/kg every other week plus oral cyclophosphamide 50 mg daily until disease progression or undue toxicity. Adverse events were graded according to the NCI Common Toxicity Criteria. Response rates were determined by CA-125 levels or changes in target lesions according to RECIST.
Fifteen patients were treated. Median age was 57 years (range 42-69). The median number of previous chemotherapy regimens was 8 (range 5-15). The median time from the first diagnosis to treatment with bevacizumab was 68.9 months (range, 26.5-177.2). The median number of bevacizumab infusions was 8 (range, 2-12), and the total number was 113. Two patients (13.3%) had a complete response after 4 months of therapy. Six patients (40.0%) had a partial response. The median duration of this response was 3.9 months (range, 2.3-10.4). Three patients (20%) had stable disease of 4.0, 5.2 and 5.5 months' duration, and 4 patients (26.7%) had progressive disease. Despite being heavily pre-treated and having confirmed intra-abdominal cancer, no gastrointestinal perforations developed. Other toxicities included: grade 3 pancreatitis in 1 patient; grade 2 proteinuria and hypertension in another, which resolved with the cessation of bevacizumab.
In our population of very heavily pre-treated patients, with at least five prior regimens, bevacizumab in combination with oral cyclophosphamide has significant activity with a response rate of 53%, without significant toxicity.
探讨贝伐单抗在多次接受治疗的复发性卵巢癌患者中的疗效和安全性。
复发性卵巢癌患者接受静脉注射贝伐单抗10mg/kg，每两周一次，加口服环磷酰胺每日50mg，直至疾病进展或出现不可耐受的毒性。不良事件根据美国国立癌症研究所通用毒性标准进行分级。缓解率根据CA-125水平或依据实体瘤疗效评价标准（RECIST）的靶病灶变化来确定。
15例患者接受了治疗。中位年龄为57岁（范围42 - 69岁）。既往化疗方案的中位数为8个（范围5 - 15个）。从首次诊断到接受贝伐单抗治疗的中位时间为68.9个月（范围26.5 - 177.2个月）。贝伐单抗输注的中位数为8次（范围2 - 12次），总数为113次。2例患者（13.3%）在治疗4个月后完全缓解。6例患者（40.0%）部分缓解。该缓解的中位持续时间为3.9个月（范围2.3 - 10.4个月）。3例患者（20%）病情稳定，持续时间分别为4.0、5.2和5.5个月，4例患者（26.7%）疾病进展。尽管患者接受了大量前期治疗且已确诊腹腔内癌症，但未发生胃肠道穿孔。其他毒性包括：1例患者发生3级胰腺炎；另1例患者出现2级蛋白尿和高血压，停用贝伐单抗后缓解。
在我们这群接受过大量前期治疗、至少接受过五种先前方案治疗
